Agios Pharmaceuticals, Inc. (NASDAQ:AGIO), a leader in the field of
cellular metabolism to treat cancer and rare genetic diseases,
today announced that mitapivat and ivosidenib clinical data will be
presented at the European Hematology Association (EHA) Annual
Congress being held virtually June 11-14, 2020.
The accepted abstracts are listed below and are available online
on the EHA meeting library website:
https://eha25-eha.web.indrina.com/abstracts. All presentations can
be accessed on demand by registered meeting attendees on the EHA
Virtual Congress platform as of Friday, June 12 at 08:30 a.m. CEST
/ 2:30 a.m. ET and will be accessible until October 15, 2020.
Oral Presentation:
Title: Proof of concept for the oral pyruvate
kinase activator mitapivat in adults with non-transfusion-dependent
thalassemia: Interim results from an ongoing, phase 2, open-label,
multicenter studyDate & Time: Friday, June 12,
2020 at 8:30 a.m. CEST / 2:30 a.m. ETOral Abstract
Session: New therapeutic approaches for thalassemia
Abstract: S297Presenter: Kevin H.
M. Kuo, M.D., Toronto General Hospital
Poster Presentations:
Title: Mitapivat (AG-348) long-term safety and
efficacy in pyruvate kinase deficiency: 3-year results of the Drive
PK studyPoster Session: Enzymopathies,
membranopathies and other anemiasAbstract:
EP1561Author: Rachael F. Grace, M.D., Boston
Children’s Hospital
Title: Ivosidenib improves overall survival
relative to standard therapies in relapsed or refractory mutant
IDH1 AML: Results from matched comparisons to historical
controlsPoster Session: Acute myeloid leukemia -
ClinicalAbstract: EP540Author:
Peter Paschka, M.D., Universitätsklinikum Ulm
Title: Ivosidenib (IVO) in patients with
IDH1-mutant relapsed/refractory myelodysplastic syndrome (R/R MDS):
Updated enrollment of a phase 1 dose escalation and expansion
studyPoster Session: Myelodysplastic syndromes -
Clinical Abstract: EP826Author:
Courtney D. DiNardo, M.D., University of Texas MD Anderson Cancer
Center
Title: Pharmacokinetic/pharmacodynamic
evaluation of ivosidenib or enasidenib combined with intensive
induction and consolidation chemotherapy in patients with newly
diagnosed IDH1/2-mutant AMLPoster Session: Acute
myeloid leukemia - ClinicalAbstract:
EP620Author: Yue Chen, Agios Pharmaceuticals
Title: Ivosidenib (IVO) prior to hematopoietic
cell transplant for patients with IDH1-mutant relapsed or
refractory acute myeloid leukemia (R/R AML)Poster
Session: Acute myeloid leukemia -
ClinicalAbstract: EP577Author:
Courtney D. DiNardo, M.D., University of Texas MD Anderson Cancer
Center
Publication Only:
Title: Agile: Phase 3, double-blind,
randomized, placebo-controlled study of ivosidenib in combination
with azacitidine in adults with newly diagnosed acute myeloid
leukemia and an IDH1 mutationPublication Only (in abstract
book): 04. Acute myeloid leukemia -
ClinicalAbstract: PB1862Author:
Pau Montesinos, M.D., Ph.D., Hospital Universitari i Politècnic La
Fe
Conference Call InformationAgios will host a
virtual investor event on June 12, 2020 at 7:30 a.m. ET to review
the mitapivat clinical data. The event will be webcast live and can
be accessed under "Events & Presentations" in the Investors and
Media section of the company's website at www.agios.com. The
archived webcast will be available on the company's website
beginning approximately two hours after the event.
About AgiosAgios is focused on discovering and
developing novel investigational medicines to treat malignant
hematology, solid tumors and rare genetic diseases through
scientific leadership in the field of cellular metabolism. In
addition to an active research and discovery pipeline across these
three therapeutic areas, Agios has two approved oncology precision
medicines and multiple first-in-class investigational therapies in
clinical and/or preclinical development. For more information,
please visit the company's website at www.agios.com.
Cautionary Note Regarding Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
regarding the potential benefits of TIBSOVO® (ivosidenib) and
mitapivat; Agios’ plans regarding future data presentations; and
the potential benefit of its strategic plans and focus. The words
“anticipate,” “expect,” “intend,” “potential,” “milestone,” “goal,”
“will,” “on track,” “upcoming,” and similar expressions are
intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Such
statements are subject to numerous important factors, risks and
uncertainties that may cause actual events or results to differ
materially from Agios' current expectations and beliefs. For
example, there can be no guarantee that any product candidate Agios
or its collaborators is developing will successfully commence or
complete necessary preclinical and clinical development phases, or
that development of any of Agios' product candidates will
successfully continue. Moreover, there can be no guarantee that the
two approved oncology precision medicines being commercialized by
Agios and its collaborators will receive commercial acceptance.
There can be no guarantee that any positive developments in Agios'
business will result in stock price appreciation. Management's
expectations and, therefore, any forward-looking statements in this
press release could also be affected by risks and uncertainties
relating to a number of other important factors, including, without
limitation: risks and uncertainties related to the impact of the
COVID-19 pandemic to Agios’ business, operations,
strategy, goals and anticipated milestones,
including its ongoing and planned research activities,
ability to conduct ongoing and planned clinical trials, clinical
supply of current or future drug candidates, commercial supply of
current or future approved products, and launching, marketing and
selling current or future approved products; Agios’ results of
clinical trials and preclinical studies, including subsequent
analysis of existing data and new data received from ongoing and
future studies; the content and timing of decisions made by the
U.S. FDA, the EMA or other regulatory authorities,
investigational review boards at clinical trial sites and
publication review bodies; Agios’ ability to obtain and maintain
requisite regulatory approvals and to enroll patients in its
planned clinical trials; unplanned cash requirements and
expenditures; competitive factors; Agios' ability to obtain,
maintain and enforce patent and other intellectual property
protection for any product candidates it is developing; Agios’
ability to maintain key collaborations; and general economic and
market conditions. These and other risks are described in greater
detail under the caption "Risk Factors" included in Agios’ public
filings with the Securities and Exchange Commission. Any
forward-looking statements contained in this press release speak
only as of the date hereof, and Agios expressly disclaims any
obligation to update any forward-looking statements, whether as a
result of new information, future events or otherwise, except as
required by law.
Contacts
Investors:Holly Manning, 617-844-6630Director,
Investor RelationsHolly.Manning@agios.com
Media:Jessica Rennekamp, 857-209-3286Associate
Director, Corporate CommunicationsJessica.Rennekamp@agios.com
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Agios Pharmaceuticals (NASDAQ:AGIO)
Historical Stock Chart
From Apr 2023 to Apr 2024